PSNL
Personalis, Inc.
Price Chart
Latest Quote
$10.54
+0.79 (+8.10%)
Current Price
| Previous Close | $9.75 |
| Open | $10.00 |
| Day High | $10.58 |
| Day Low | $9.89 |
| Volume | 3,823,116 |
Stock Information
| Shares Outstanding | 104.72M |
| Total Debt | $38.78M |
| Cash Equivalents | $233.22M |
| Revenue | $64.52M |
| Net Income | $-95.55M |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Market Cap | $1.10B |
| EPS (TTM) | $-1.02 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $909.32M |
| Sales | $64.52M |
| Income | $-95.55M |
| Book/sh | $2.43 |
| Cash/sh | $2.23 |
| Employees | 259 |
Financial Ratios
| Quick Ratio | 6.31 |
| Current Ratio | 6.61 |
| Debt/Eq | 15.22 |
Returns & Margins
| ROA | -21.41% |
| ROE | -41.35% |
| Gross Margin | 13.72% |
| Operating Margin | -207.87% |
| Profit Margin | -148.11% |
Ownership
| Insider Ownership | 27.05% |
| Institutional Ownership | 68.18% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -11.77 |
| P/S | 17.11 |
| P/B | 4.33 |
Analyst Data
| Recommendation | none |
| Target Price | $10.86 |
Technical Indicators
| SMA20 | $10.09 |
| SMA50 | $7.76 |
| SMA200 | $8.05 |
| RSI | 42.76 |
| ATR | 0.9831 |
| Shares Float | 64.53M |
| Short Float | 19.34% |
| Short Ratio | 4.52 |
| Volatility | 2.28 |
| Rel Volume | 1.18 |
Performance History
| Week | +11.89% |
| Month | +49.72% |
| Quarter | +46.59% |
| 6 Months | +32.08% |
| YTD | +34.27% |
| Year | +69.18% |
| 3 Years | +356.28% |
| 5 Years | -53.77% |
| 10 Years | -63.00% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $10.54 | 3,823,100 |
| 2026-06-17 | $9.75 | 3,261,500 |
| 2026-06-16 | $9.69 | 2,737,300 |
| 2026-06-15 | $9.79 | 2,519,500 |
| 2026-06-12 | $9.59 | 1,965,100 |
| 2026-06-11 | $9.42 | 3,685,200 |
| 2026-06-10 | $9.61 | 2,021,000 |
| 2026-06-09 | $9.75 | 4,011,400 |
| 2026-06-08 | $10.04 | 2,341,700 |
| 2026-06-05 | $10.75 | 4,148,800 |
| 2026-06-04 | $12.10 | 5,547,000 |
| 2026-06-03 | $10.78 | 2,908,300 |
| 2026-06-02 | $11.14 | 2,422,000 |
| 2026-06-01 | $11.26 | 3,001,100 |
| 2026-05-29 | $11.40 | 4,471,500 |
| 2026-05-28 | $10.98 | 4,115,400 |
| 2026-05-27 | $9.49 | 2,459,200 |
| 2026-05-26 | $8.94 | 2,390,100 |
| 2026-05-22 | $8.47 | 2,688,200 |
| 2026-05-21 | $8.25 | 4,167,100 |
| 2026-05-20 | $7.95 | 2,697,200 |
| 2026-05-19 | $7.04 | 1,868,500 |
About Personalis, Inc.
Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for the detection of MRD; and NeXT Dx, a tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. In addition, the company performs whole exome sequencing of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing on human samples for research projects, such as population sequencing initiatives. Its services are used by pharmaceutical companies for translational research, biomarker discovery, the development of personalized cancer therapies, and for clinical trials, as well as tests are used by physicians to detect residual or recurrent cancer in patients, monitor cancer response to therapy, and uncover insights for therapy selection. The company's customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and cancer patients. The company has strategic collaboration with Tempus AI, Inc. to bring testing to colorectal cancer patients. Personalis, Inc. was incorporated in 2011 and is headquartered in Fremont, California.
đ° Latest News
Personalis CEO Sells 100,000 Company Shares Worth $1.1 Million. What Does That Mean for Investors?
Motley Fool âĸ 2026-06-04T14:51:07Z
Assessing Personalis (PSNL) Valuation After Its Strong Recent Share Price Momentum
Simply Wall St. âĸ 2026-06-01T18:11:04Z
Sector Update: Healthcare Stocks Mixed Late Afternoon
MT Newswires âĸ 2026-05-20T19:54:56Z12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga âĸ 2026-05-13T12:06:16Z
Personalis Q1 Earnings Call Highlights
MarketBeat âĸ 2026-05-08T21:07:43Z
Personalis (PSNL) Q1 2026 Earnings Transcript
Motley Fool âĸ 2026-05-08T12:37:32Z
Personalis, Inc. Q1 2026 Earnings Call Summary
Moby âĸ 2026-05-08T12:30:00Z
Personalis (PSNL) Reports Q1 Loss, Tops Revenue Estimates
Zacks âĸ 2026-05-07T23:05:06Z
How The Personalis (PSNL) Story Is Shifting With Cautious Targets And Execution Risks
Simply Wall St. âĸ 2026-05-01T11:22:31Z
Morgan Stanley Lowers Personalis (PSNL) Price Target to $10
Insider Monkey âĸ 2026-03-24T14:43:14Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $53,871,000 | $57,789,000 | $55,273,000 | $51,697,000 |
| Cost Of Revenue | $53,871,000 | $57,789,000 | $55,273,000 | $51,697,000 |
| Total Revenue | $69,648,000 | $84,614,000 | $73,481,000 | $65,047,000 |
| Operating Revenue | $68,330,000 | $84,492,000 | $73,083,000 | $64,636,000 |
| Expenses | ||||
| Interest Expense | $205,000 | $24,000 | $110,000 | $201,000 |
| Total Expenses | $157,705,000 | $152,881,000 | $169,775,000 | $180,578,000 |
| Other Income Expense | $-142,000 | $-18,485,000 | $-17,710,000 | $61,000 |
| Other Non Operating Income Expenses | $-142,000 | $-18,485,000 | $-4,068,000 | $61,000 |
| Net Non Operating Interest Income Expense | $6,950,000 | $5,486,000 | $5,791,000 | $2,195,000 |
| Interest Expense Non Operating | $205,000 | $24,000 | $110,000 | $201,000 |
| Operating Expense | $103,834,000 | $95,092,000 | $114,502,000 | $128,881,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-81,270,000 | $-81,284,000 | $-108,296,000 | $-113,315,000 |
| Net Interest Income | $6,950,000 | $5,486,000 | $5,791,000 | $2,195,000 |
| Interest Income | $7,155,000 | $5,510,000 | $5,901,000 | $2,396,000 |
| Normalized Income | $-81,270,000 | $-81,284,000 | $-94,654,000 | $-113,315,000 |
| Net Income From Continuing And Discontinued Operation | $-81,270,000 | $-81,284,000 | $-108,296,000 | $-113,315,000 |
| Total Operating Income As Reported | $-88,057,000 | $-68,267,000 | $-109,936,000 | $-115,531,000 |
| Net Income Common Stockholders | $-81,270,000 | $-81,284,000 | $-108,296,000 | $-113,315,000 |
| Net Income | $-81,270,000 | $-81,284,000 | $-108,296,000 | $-113,315,000 |
| Net Income Including Noncontrolling Interests | $-81,270,000 | $-81,284,000 | $-108,296,000 | $-113,315,000 |
| Net Income Continuous Operations | $-81,270,000 | $-81,284,000 | $-108,296,000 | $-113,315,000 |
| Pretax Income | $-81,249,000 | $-81,266,000 | $-108,213,000 | $-113,275,000 |
| Interest Income Non Operating | $7,155,000 | $5,510,000 | $5,901,000 | $2,396,000 |
| Operating Income | $-88,057,000 | $-68,267,000 | $-96,294,000 | $-115,531,000 |
| Gross Profit | $15,777,000 | $26,825,000 | $18,208,000 | $13,350,000 |
| Special Income Charges | - | $0 | $-13,642,000 | $0 |
| Per Share | ||||
| Diluted EPS | $-0.91 | $-1.37 | $-2.25 | $-2.48 |
| Basic EPS | $-0.91 | $-1.37 | $-2.25 | $-2.48 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-70,998,000 | $-70,301,000 | $-83,165,000 | $-104,642,000 |
| Reconciled Depreciation | $10,046,000 | $10,941,000 | $11,296,000 | $8,432,000 |
| EBITDA (Bullshit earnings) | $-70,998,000 | $-70,301,000 | $-96,807,000 | $-104,642,000 |
| EBIT | $-81,044,000 | $-81,242,000 | $-108,103,000 | $-113,074,000 |
| Diluted Average Shares | $89,240,435 | $59,251,013 | $48,175,201 | $45,704,805 |
| Basic Average Shares | $89,240,435 | $59,251,013 | $48,175,201 | $45,704,805 |
| Diluted NI Availto Com Stockholders | $-81,270,000 | $-81,284,000 | $-108,296,000 | $-113,315,000 |
| Tax Provision | $21,000 | $18,000 | $83,000 | $40,000 |
| Research And Development | $50,264,000 | $48,905,000 | $64,776,000 | $64,912,000 |
| Selling General And Administration | $53,570,000 | $46,187,000 | $49,726,000 | $63,969,000 |
| Total Unusual Items | - | $0 | $-13,642,000 | $0 |
| Total Unusual Items Excluding Goodwill | - | $0 | $-13,642,000 | $0 |
| Impairment Of Capital Assets | - | $0 | $5,565,000 | $0 |
| Restructuring And Mergern Acquisition | - | $0 | $8,077,000 | $0 |
Fetched: 2026-06-20
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $261,185,000 | $202,957,000 | $129,441,000 | $218,139,000 |
| Total Assets | $334,164,000 | $270,268,000 | $225,099,000 | $292,700,000 |
| Total Non Current Assets | $66,213,000 | $67,253,000 | $78,355,000 | $93,001,000 |
| Other Non Current Assets | $6,280,000 | $2,526,000 | $3,137,000 | $4,586,000 |
| Current Assets | $267,951,000 | $203,015,000 | $146,744,000 | $199,699,000 |
| Other Current Assets | $5,651,000 | $3,927,000 | $4,361,000 | $6,808,000 |
| Current Deferred Assets | $887,000 | $1,963,000 | $4,813,000 | $2,207,000 |
| Inventory | $5,257,000 | $3,976,000 | $5,661,000 | $6,384,000 |
| Receivables | $16,203,000 | $8,140,000 | $17,730,000 | $16,642,000 |
| Accounts Receivable | $16,203,000 | $8,140,000 | $17,730,000 | $16,642,000 |
| Cash Cash Equivalents And Short Term Investments | $239,953,000 | $185,009,000 | $114,179,000 | $167,658,000 |
| Cash And Cash Equivalents | $124,245,000 | $91,415,000 | $56,984,000 | $89,128,000 |
| Cash Equivalents | $119,326,000 | $90,263,000 | $53,335,000 | $83,513,000 |
| Cash Financial | $4,919,000 | $1,152,000 | $3,649,000 | $5,615,000 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $39,948,000 | $44,247,000 | $47,728,000 | $48,650,000 |
| Long Term Debt And Capital Lease Obligation | $31,866,000 | $34,882,000 | $38,321,000 | $41,041,000 |
| Current Debt And Capital Lease Obligation | $8,082,000 | $9,365,000 | $9,407,000 | $7,609,000 |
| Current Debt | $1,190,000 | $1,669,000 | $1,646,000 | $2,218,000 |
| Other Current Borrowings | $1,190,000 | $1,669,000 | $1,646,000 | $2,218,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $72,979,000 | $67,311,000 | $95,658,000 | $74,561,000 |
| Total Non Current Liabilities Net Minority Interest | $33,349,000 | $36,185,000 | $48,424,000 | $41,430,000 |
| Other Non Current Liabilities | $1,483,000 | $1,303,000 | $5,161,000 | $389,000 |
| Current Liabilities | $39,630,000 | $31,126,000 | $47,234,000 | $33,131,000 |
| Other Current Liabilities | $5,459,000 | $2,019,000 | $6,492,000 | - |
| Current Deferred Liabilities | $1,562,000 | $3,100,000 | $3,288,000 | $1,294,000 |
| Payables And Accrued Expenses | $17,189,000 | $7,797,000 | $14,920,000 | $14,677,000 |
| Payables | $12,989,000 | $6,397,000 | $14,920,000 | $12,977,000 |
| Accounts Payable | $12,989,000 | $6,397,000 | $14,920,000 | $12,854,000 |
| Derivative Product Liabilities | - | $0 | $4,942,000 | $0 |
| Total Tax Payable | - | - | $37,000 | $123,000 |
| Equity | ||||
| Common Stock Equity | $261,185,000 | $202,957,000 | $129,441,000 | $218,139,000 |
| Total Equity Gross Minority Interest | $261,185,000 | $202,957,000 | $129,441,000 | $218,139,000 |
| Stockholders Equity | $261,185,000 | $202,957,000 | $129,441,000 | $218,139,000 |
| Gains Losses Not Affecting Retained Earnings | $104,000 | $-23,000 | $-222,000 | $-912,000 |
| Other Equity Adjustments | $104,000 | $-23,000 | $-222,000 | $-912,000 |
| Retained Earnings | $-631,260,000 | $-549,990,000 | $-468,706,000 | $-360,410,000 |
| Other | ||||
| Ordinary Shares Number | $102,475,891 | $85,171,146 | $50,480,694 | $46,707,084 |
| Share Issued | $102,475,891 | $85,171,146 | $50,480,694 | $46,707,084 |
| Tangible Book Value | $261,185,000 | $202,957,000 | $129,441,000 | $218,139,000 |
| Invested Capital | $262,375,000 | $204,626,000 | $131,087,000 | $220,357,000 |
| Working Capital | $228,321,000 | $171,889,000 | $99,510,000 | $166,568,000 |
| Capital Lease Obligations | $38,758,000 | $42,578,000 | $46,082,000 | $46,432,000 |
| Total Capitalization | $261,185,000 | $202,957,000 | $129,441,000 | $218,139,000 |
| Additional Paid In Capital | $892,331,000 | $752,961,000 | $598,364,000 | $579,456,000 |
| Capital Stock | $10,000 | $9,000 | $5,000 | $5,000 |
| Common Stock | $10,000 | $9,000 | $5,000 | $5,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $31,866,000 | $34,882,000 | $38,321,000 | $41,041,000 |
| Current Deferred Revenue | $1,562,000 | $3,100,000 | $3,288,000 | $1,294,000 |
| Current Capital Lease Obligation | $6,892,000 | $7,696,000 | $7,761,000 | $5,391,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $7,338,000 | $8,845,000 | $13,127,000 | $9,551,000 |
| Current Accrued Expenses | $4,200,000 | $1,400,000 | $0 | $1,700,000 |
| Net PPE | $59,933,000 | $64,727,000 | $75,218,000 | $88,415,000 |
| Accumulated Depreciation | $-53,911,000 | $-46,038,000 | $-37,668,000 | $-26,926,000 |
| Gross PPE | $113,844,000 | $110,765,000 | $112,886,000 | $115,341,000 |
| Leases | $41,691,000 | $41,556,000 | $40,811,000 | $40,370,000 |
| Construction In Progress | $56,000 | $899,000 | $3,485,000 | $3,989,000 |
| Other Properties | $15,118,000 | $16,453,000 | $17,852,000 | $26,480,000 |
| Machinery Furniture Equipment | $56,979,000 | $51,857,000 | $50,738,000 | $44,502,000 |
| Properties | $0 | $0 | $0 | $0 |
| Raw Materials | $5,257,000 | $3,976,000 | $5,661,000 | $6,384,000 |
| Other Short Term Investments | $115,708,000 | $93,594,000 | $57,195,000 | $78,530,000 |
Fetched: 2026-06-20
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-79,450,000 | $-46,753,000 | $-67,169,000 | $-120,129,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-74,946,000 | $-45,150,000 | $-56,258,000 | $-70,233,000 |
| Cash Flow From Continuing Operating Activities | $-74,946,000 | $-45,150,000 | $-56,258,000 | $-70,233,000 |
| Operating Gains Losses | - | $18,274,000 | $4,027,000 | - |
| Investing Activities | ||||
| Capital Expenditure | $-4,504,000 | $-1,603,000 | $-10,911,000 | $-49,896,000 |
| Investing Cash Flow | $-22,568,000 | $-35,069,000 | $13,099,000 | $52,537,000 |
| Cash Flow From Continuing Investing Activities | $-22,568,000 | $-35,069,000 | $13,099,000 | $52,537,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $126,797,000 | $97,824,000 | $3,513,000 | $0 |
| Financing Cash Flow | $130,338,000 | $114,672,000 | $11,031,000 | $1,366,000 |
| Cash Flow From Continuing Financing Activities | $130,338,000 | $114,672,000 | $11,031,000 | $1,366,000 |
| Net Other Financing Charges | $-189,000 | $-1,230,000 | - | - |
| Net Common Stock Issuance | $126,797,000 | $97,824,000 | $3,513,000 | $0 |
| Common Stock Issuance | $126,797,000 | $97,824,000 | $3,513,000 | $0 |
| Other | ||||
| Repayment Of Debt | $-2,002,000 | $-1,130,000 | $-3,264,000 | $-2,293,000 |
| Issuance Of Debt | $2,587,000 | $0 | $3,438,000 | $1,194,000 |
| Income Tax Paid Supplemental Data | $23,000 | $38,000 | $64,000 | $47,000 |
| End Cash Position | $126,035,000 | $93,205,000 | $58,774,000 | $90,918,000 |
| Beginning Cash Position | $93,205,000 | $58,774,000 | $90,918,000 | $107,375,000 |
| Effect Of Exchange Rate Changes | $6,000 | $-22,000 | $-16,000 | $-127,000 |
| Changes In Cash | $32,824,000 | $34,453,000 | $-32,128,000 | $-16,330,000 |
| Proceeds From Stock Option Exercised | $3,145,000 | $19,208,000 | $7,344,000 | $2,465,000 |
| Net Issuance Payments Of Debt | $585,000 | $-1,130,000 | $174,000 | $-1,099,000 |
| Net Long Term Debt Issuance | $585,000 | $-1,130,000 | $174,000 | $-1,099,000 |
| Long Term Debt Payments | $-2,002,000 | $-1,130,000 | $-3,264,000 | $-2,293,000 |
| Long Term Debt Issuance | $2,587,000 | $0 | $3,438,000 | $1,194,000 |
| Net Investment Purchase And Sale | $-18,064,000 | $-33,708,000 | $24,010,000 | $102,433,000 |
| Sale Of Investment | $192,110,000 | $88,000,000 | $127,955,000 | $223,923,000 |
| Purchase Of Investment | $-210,174,000 | $-121,708,000 | $-103,945,000 | $-121,490,000 |
| Net PPE Purchase And Sale | $-4,504,000 | $-1,361,000 | $-10,911,000 | $-49,896,000 |
| Sale Of PPE | $0 | $242,000 | $0 | - |
| Purchase Of PPE | $-4,504,000 | $-1,603,000 | $-10,911,000 | $-49,896,000 |
| Change In Working Capital | $-10,193,000 | $-2,592,000 | $13,482,000 | $10,611,000 |
| Change In Other Working Capital | $-1,538,000 | $-4,116,000 | $5,952,000 | $-2,718,000 |
| Change In Other Current Liabilities | $-5,020,000 | $-2,305,000 | $884,000 | $12,392,000 |
| Change In Payables And Accrued Expense | $6,856,000 | $-11,325,000 | $5,920,000 | $1,610,000 |
| Change In Accrued Expense | $2,306,000 | $-2,401,000 | $742,000 | $-1,479,000 |
| Change In Payable | $4,550,000 | $-8,924,000 | $5,178,000 | $3,089,000 |
| Change In Account Payable | $4,550,000 | $-8,924,000 | $5,178,000 | $3,089,000 |
| Change In Prepaid Assets | $-2,224,000 | $1,139,000 | $3,748,000 | $484,000 |
| Change In Inventory | $-204,000 | $4,425,000 | $-1,934,000 | $-2,982,000 |
| Change In Receivables | $-8,063,000 | $9,590,000 | $-1,088,000 | $1,825,000 |
| Changes In Account Receivables | $-8,063,000 | $9,590,000 | $-1,088,000 | $1,825,000 |
| Other Non Cash Items | $1,033,000 | $1,492,000 | $5,617,000 | $4,549,000 |
| Stock Based Compensation | $9,429,000 | $10,686,000 | $14,051,000 | $19,433,000 |
| Amortization Of Securities | $-3,991,000 | $-2,667,000 | $-2,000,000 | $57,000 |
| Depreciation Amortization Depletion | $10,046,000 | $10,941,000 | $11,296,000 | $8,432,000 |
| Depreciation And Amortization | $10,046,000 | $10,941,000 | $11,296,000 | $8,432,000 |
| Net Income From Continuing Operations | $-81,270,000 | $-81,284,000 | $-108,296,000 | $-113,315,000 |
| Asset Impairment Charge | - | $0 | $5,565,000 | $0 |
| Gain Loss On Investment Securities | - | $18,274,000 | $4,027,000 | - |
| Interest Paid Supplemental Data | - | - | $0 | $0 |
Fetched: 2026-06-20